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ABSTRACT 
Background:  Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and 
migration.  The purpose of this study was to determine the maximum tolerated dose (MTD), safety, 
pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer 
patients. 
Patients and methods:  The dose of GSK2256098 was escalated in cohorts of patients with advanced 
cancer from 80 to 1500 mg, oral twice daily (BID), until the MTD was determined.  Serial blood samples 
were obtained from all patients and the PK determined.  Paired tumor biopsies were obtained in select 
patients and the level of phospho-FAK (pFAK) determined. 
Results:  Sixty-two patients (39 males, 23 females; median age 61 y.o., range 21-84) received 
GSK2256098.  Dose-limiting toxicities of grade 2 proteinuria (1000 mg BID), grade 2 fatigue, nausea, 
vomiting (1250 mg BID), and grade 3 asthenia and grade 2 fatigue (1500 mg BID) were reported with the 
MTD identified as 1000 mg BID.  The most frequent adverse events (AEs) were nausea (76%), diarrhea 
(65%), vomiting (58%), and decreased appetite (47%) with the majority of AEs being grade 1-2.  The PK 
was generally dose proportional with a geometric mean elimination half-life range of 4-9 hours.  At the 
750, 1000, and 1500 mg BID dose levels evaluated, the pFAK, Y397 autophosphorylation site, was 
reduced by ~80% from baseline.  Minor responses were observed in a patient with melanoma (-26%) 
and three patients with mesothelioma (-13%, -15%, -17%).  In the 29 patients with recurrent 
mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 
weeks merlin negative, n=14; 11.4 weeks merlin positive, n=9; 10.9 wks merlin status unknown, n=6). 
Conclusions:  GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses 
at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with 
merlin loss. 
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Introduction 
Focal adhesion kinase (FAK, protein tyrosine kinase 2) is a non-receptor tyrosine kinase required for 
cancer cell growth, proliferation, survival, migration, angiogenesis, invasion and mesenchymal 
transformation [1].  Recent data indicate that FAK may be important in the maintenance of cancer stem 
cells and in macrophage activation [1, 2].  Over-expression of FAK (gene or protein) has been reported in 
several cancers, including breast, colorectal, head and neck, endometrium, lung, ovarian, pancreas, 
prostate, stomach, thyroid, and other solid tumors [3, 4] and hematologic cancers [5, 6].  FAK expression 
increases as tumors become more advanced and is associated with poor survival in ovarian, glioma, and 
acute myelogenous leukemia [6, 7, 8].   
GSK2256098 is a potent, ATP-competitive inhibitor of FAK kinase activity and is highly selective for FAK 
with a ~1000 fold selectivity over the nearest family member PYK2 [9].  Inhibition of FAK kinase activity 
has also been demonstrated in cells and in vivo as determined by decreased levels of pFAK in a 
concentration dependent manner [9].  In vitro cellular studies demonstrate that GSK2256098 inhibits 
cancer cell growth and induces apoptosis in cell selective and growth-dependent conditions [9].  
GSK2256098 also inhibits cell migration, invasion [10], and angiogenesis [GSK internal data and 10].  As a 
single agent and in combination with other anticancer agents, GSK2256098 has demonstrated activity in 
in vivo models of ovarian cancer and glioblastoma [9, 11, 12].   
The purpose of this first in cancer patient study was to determine the maximum tolerated dose (MTD), 
safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of GSK2256098 
in patients with advanced solid tumors.   
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PATIENTS AND METHODS 
Patient selection 
Signed, written informed consent was obtained from all patients and the study was approved by 
independent ethics committee.  Patients, ≥ 18 years of age, with histologically confirmed, advanced 
solid tumors that were not responsive to standard therapy were eligible.  For Part 1 of the study (see 
study design below), patients with advanced solid tumors reported in the medical literature to 
overexpress FAK were eligible.  For Parts 2 and 3, patients with mesothelioma or cancers of the ovary, 
pancreas, head and neck, stomach, endometrium, non-small cell lung, and prostate were eligible. Other 
eligibility criteria included ECOG performance status of 0-1, adequate organ function (hematologic, 
hepatic, renal), and ability to swallow oral medications.  Female patients of child-bearing potential were 
required to comply with protocol-defined contraceptive methods.  Patients with symptomatic brain 
metastases requiring steroids or anti-convulsant therapy were not eligible to participate.   
Study design 
This was a three-part Phase I study; Part 1 (Dose Escalation), Part 2 (Safety Expansion), and Part 3 (PD) 
(NCT01138033).  Patients received GSK2256098, orally twice daily, with a light meal (see online 
supplemental material for details), until unacceptable toxicity, disease progression, or withdrawal of 
consent.  For Part 1, Dose Escalation, a Modified Acceleration Titration design [13] was used permitting 
100% dose increases in single patient dose cohorts until a total of two patients in any cohort developed 
Grade 2 toxicities within the first 21-day dosing period or one subject developed a DLT.  At that point, a 
standard 3 + 3 design was used.  The MTD was defined as the dose level where ≤ 1 of up to 6 patients 
had a dose-limiting toxicity within the first 21 days.  Dose limiting toxicity (DLT) was identified as NCI 
CTCAE v4.0 grade 3 or 4 non-hematologic toxicity (excluding nausea, vomiting, diarrhea without 
adequate supportive care), grade 4 neutropenia > 5 days, febrile neutropenia, grade 4 
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anemia/thrombocytopenia, toxicity that resulted in ≥ 7 days of drug interruption (continuous or not) in 
the first 21 days, or any toxicity ≥ Grade 2 that in judgment of the study investigator was dose-limiting. 
 
Study endpoints and assessments 
Adverse events (AEs) were assessed continuously through the study with CTCAE v4.0.  Hematology, 
urinalysis, clinical chemistry, and electrocardiograms were assessed at baseline, on Day 1, 8, 15, 22, then 
every three weeks thereafter.  Fasting lipid panels were performed at baseline and day 22, day 43 then 
every 6 weeks. Disease assessments were performed at baseline and every six weeks and response 
assessed using RECIST 1.1 [14].  In patients with malignant pleural mesothelioma, their scans were also 
reviewed independently using Modified RECIST for Mesothelioma [15]. 
Translational research  
Pharmacokinetics 
Whole blood samples (2 mL) were collected during Parts 1-3 of the study and specific details regarding 
PK studies are found in the Supplemental materials online.   
Tumor biopsy collection and determination of pFAK levels 
Tumor biopsies were mandatory for patients in Part 3 and optional for those in Parts 1 and 2.  Paired 
tumor biopsies were collected prior to dosing on Day 1 and on a day between Days 8-15, one to six 
hours after dosing.   Details regarding the pFAK analysis methods are found in the Supplemental 
materials online.   
Evaluation of circulating tumor, endothelial, and endothelial progenitor cells 
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Details and references [16, 17, 18] regarding the evaluation of CTCs, CECs, and CEPs are found in the 
Supplemental materials online.  
Determination of merlin status 
 Paraffin-embedded, archival tumor samples were required for all patients.  Merlin (the protein product 
of the gene neurofibromin 2 or NF2) status was determined by immunohistochemistry of formalin fixed 
paraffin embedded (FFPE) archival samples collected from patients with mesothelioma (n=29) and a 
patient with melanoma (n=1).  Details regarding the analysis of archival tumor samples for merlin 
expression are found in the Supplemental materials online.  
 Statistical analysis 
The primary focus was the determination of the MTD, the safety profile, to identify a range of 
biologically active doses, and to determine the PK and PD of GSK2256098 in patients with solid tumors.  
The analyses were primarily descriptive or exploratory for toxicity, DLTs, and MTD.  An exploratory 
analysis of progression-free survival (PFS) was conducted for the group of patients with mesothelioma.  
PFS was defined as the time from date of first dose of study drug to the date of first documented 
disease progression according to radiological or clinical assessment, or to date of death due to any 
cause.  For patients who did not progress or die, PFS was censored at the time of last radiological 
disease assessment. Patients who discontinued the study with no post treatment tumor assessment 
were censored at date of first dose of study drug.  Summaries of PFS and Kaplan-Meier curves were 
produced for all mesothelioma patients together and separately by merlin status. 
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RESULTS 
Sixty-two patients were entered into the study and received at least one dose of GSK2256098.  All 
patients had progressive disease of their tumor at study entry.  Patient characteristics are provided in 
Table 1.  Mesothelioma was the most common tumor type (n=29), and the rationale for enrollment of 
this tumor type is found below in Results and Discussion sections below.  There were 26, 26, and 10 
patients enrolled in Parts 1 (Dose Escalation), 2 (Safety Expansion), and 3 (Pharmacodynamics) of the 
study respectively.  
Determination of the MTD 
A summary of the dose levels evaluated and DLTs during Part 1 are provided in Table 2.  One DLT was 
observed at the 1000 mg dose level, defined by reversible Grade 2 proteinuria (elevation in urine 
protein:creatinine (UPC) ratio requiring a protocol mandated dose reduction).  The cohort was expanded 
to six patients at 1000 mg BID and was well-tolerated. Three patients were enrolled at the 1500 mg BID 
dose level, one had a DLT of Grade 3 asthenia. An additional two patients were enrolled and one had 
Grade 2 fatigue that was also considered dose limiting.  Since the MTD was exceeded, an intermediate 
dose cohort of 1250 mg BID was enrolled with three patients.  One patient had a DLT of grade 2 nausea, 
vomiting, and fatigue and a further 2 were enrolled. As overall tolerability to drug was poor at this level, 
no further enrollment occurred and 1000 mg BID was declared as the MTD. 
Safety 
A summary of AEs by dose, regardless of attribution, is provided in Table 3.  The majority of AEs were 
grade 1-2 in severity with the four most frequent AEs being nausea, diarrhea, vomiting, and decreased 
appetite.  The most frequent grade 3 AEs were hypertriglyceridemia, occurring in 3 patients (5%) and all 
at 1000 mg BID and hypokalemia occurring in 3 patients (5%), one at 750 mg BID and two at 1000 mg 
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BID.    Two grade 4 AEs were reported, one patient with elevated blood creatinine phosphokinase and 
one patients with a cerebrovascular accident.  Neither of these events was attributed to GSK2256098.  
Clinical laboratory AEs ≥ 20% included proteinuria (26%), hyperbilirubinemia (23%), and 
hypercholesterolemia (21%). 
Dose reductions and interruptions 
Dose reductions due to AEs occurred in seven (11%) patients, with nausea being the commonest reason 
(three patients, 5%).  At the MTD of 1000mg BID (41 patients), there were six patients (15%) with dose 
reductions due to AEs with nausea being the most common reason (5%).  Dose interruptions due to AEs 
occurred in 17 patients (27%).  The AEs leading to dose interruptions included fatigue (6%), nausea (5%), 
vomiting (5%), decreased appetite (3%), diarrhea (3%), pleural effusion (3%), and pleuritic pain (3%).  At 
the MTD of 1000mg BID (41 patients), 15 patients (37%) had dose interruptions due to AEs with fatigue, 
diarrhea, pleural effusion, and pleuritic pain (each 5%) being the most common reasons. 
Pharmacokinetic analyses 
When administered with a light meal on Day 1, GSK2256098 was rapidly absorbed (median tmax 1.5 to 4 
hrs). The geometric mean half-life ranged between 4.0 and 9.0 hours. The Cmax and AUC, over the dose 
range of 80 to 1500 mg, were generally dose proportional after single and repeat dosing.  A summary of 
the pharmacokinetics of GSK2256098 on Day 1 and 15 are provided in Table 4.  The Cmax and AUC of 
GSK2256098 were lower after repeat dosing compared to Day 1 values. 
Pharmacodynamic analyses 
The percent decrease in Y397 pFAK/total FAK in paired pre- and on-treatment biopsy samples was 
determined from six patients at dose levels 750 mg BID , 1000 mg BID, and 1500 mg BID and was 80% or 
greater in 5 of 6 patients (Figure 1).    
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Circulating cells 
CTCs, CECs, and CEPs were collected and analyzed at one clinical research center (GR).  CECs were not 
affected by GSK2256098 treatment.  CTCs were very low before and following treatment and no change 
was observed.  However, a median decrease of 19% in CEPs from baseline values was noted.   
Merlin analysis 
Tumor tissue from 23 patients (79%) with mesothelioma was available for merlin evaluation by IHC 
analysis.  Samples were either not available or not evaluable for 6 patients. Tissue from 14 patients 
(48%) stained negative for merlin indicating the putative loss of protein in these samples and the tissue 
from nine patients stained positive. One melanoma subject tested was identified as merlin negative 
Clinical activity 
A best response of stable disease was achieved in 28 patients (45%).  In patients with measurable 
disease, changes in tumor size from baseline by RECIST, duration on treatment, and patient tumor type 
are shown in Figure 2. A summary of minor responses or prolonged stable disease are provided in Table 
5.  One patient with nasopharyngeal cancer had a 31% decrease from baseline in his target lesions but at 
the same scan date had a new lesion and was removed from the study due to progressive disease.  In 
patients with malignant pleural mesothelioma, the overall median PFS (95% CI) was 12 weeks (9.1, 23.4).  
In patients with merlin negative mesothelioma (n=14), merlin positive (n=9), or unknown (n=6), the 
median PFS (95% CI) was 23.4 (6.0, 28.1), 11.4 (4.3, 22.6), and 10.9 (9.1, not determined) weeks 
respectively.  
DISCUSSION 
The importance of FAK in multiple biological processes of cancer, including invasion and metastases 
means that targeting FAK is a rational treatment strategy.  An earlier single-dose, dose ranging, first time 
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in human study evaluated the pharmacokinetics, safety, and food effect in healthy volunteers 
(NCT00996671).  The current study described here is the first in cancer patient and repeat-dose study of 
GSK2256098, an oral selective inhibitor of FAK, in a patient population with advanced and metastatic 
cancers.  In this study the safety, PK, and clinical activity were evaluated over a dose range of 80 to 1500 
mg BID and tumor PD was performed at doses of 750, 1000, and 1500 mg BID.   
GSK2256098 had an acceptable safety profile at and below the MTD.  Overall, the majority of AEs were 
Grade 1-2 in severity.  Gastrointestinal AEs were the most common AEs and were the major reason for 
dose reductions and interruptions.  Reversible proteinuria, seen at doses of 750 mg twice daily and 
higher, was present in 26% of patients and was observed during preclinical studies at high doses in 28-
day preclinical safety studies in rats and dogs (GSK internal data).  Increases in total and direct bilirubin 
were observed.  Increased total bilirubin was also seen in 28-day preclinical animal safety studies 
although only total bilirubin was measured (GSK internal data).  In vitro, GSK2256098 is an inhibitor of 
UGT1A1 at concentrations achieved in this study.  Elevated cholesterol and triglycerides was also seen in 
the current study and in preclinical animal safety studies.  The mechanism for this increase is unclear.   
At the MTD dose of 1000 mg  BID, a reduction in Cmax and AUC were observed on Day 15 compared to 
Day 1, while a comparison of the the terminal elimination phases appeared similar (i.e. were parallel) 
between the two days. This finding suggests a change in bioavailability, perhaps due to changes in 
absorption with repeat dosing, rather than an alteration in systemic clearance.  Autoinduction of key 
drug metabolizing enzymes in the gut resulting in a reduction in Cmax and AUC is one potential 
explanation for the reduction.  Additional pharmacokinetic sampling and in vitro data are required to 
fully understand the mechanism of these changes. 
Target engagement (decreased pFAK from baseline) was observed in multiple tumor types and was 
similar across the dose range of 750, 1000, and 1500 mg BID, the only doses at which biopsies were 
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obtained.  No correlation was observed between different measures of GSK2256098 systemic exposure 
and pFAK inhibition, possibly due to concentrations being in the range of maximal response on the dose-
response curve for target engagement. Given that minor tumor responses were seen across the range of 
doses evaluated, including at the very first dose evaluated at 80 mg BID, it would be of interest to see if 
target inhibition is occurring at lower doses.  An ongoing clinical study of GSK2256098 is evaluating pFAK 
inhibition at lower GSK2256098 doses (FAK114746) in combination with trametinib. At doses of 250 mg 
and 500 mg twice daily of GSK2256098, pFAK is reduced by more than 80 and 60% respectively [19]. 
During the conduct of the study, a patient with malignant pleural mesothelioma in the 300 mg BID 
cohort, with four prior regimens, was noted to have a 15% decrease in tumor size.  Upon treatment with 
GSK2256098, this patient continued on therapy for 191 days.  Analysis of the patient’s archival tumor 
sample indicated that the tumor was merlin negative.  Merlin is a tumor suppressor frequently lost (40-
50%) in mesothelioma [20].  In mesothelioma cell lines, merlin negative cells have increased 
invasiveness and FAK expression [21].  Auger et al demonstrated that merlin negative mesothelioma cell 
lines were >100X more sensitive that a merlin positive cell line to GSK2256098 [9]. Shapiro et al have 
also noted increased sensitivity of merlin negative mesothelioma cells to a small molecule inhibitor of 
FAK [22].   Although merlin negative mesothelioma cells have greater sensitivity to GSK2256098, 
antitumor activity is also seen in a merlin positive mesothelioma cell line [9]. Based on the clinical and 
laboratory findings noted above, additional enrollment of patients with mesothelioma was encouraged.  
PFS in recurrent mesothelioma is poor with a recent Phase 3 study of vorinostat versus placebo in 
recurrent mesothelioma reporting a median 6 week PFS in the treatment and placebo groups [23].  In 
both merlin negative and merlin positive mesothelioma patients, the PFS for both groups was greater 
was noted in the vorinostat study thus supporting the finding in the in vitro studies of GSK2256098 
noted above [9] that activity is present in both merlin groups.  The current study is unable to determine 
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whether merlin negativity is a prognostic or predictive biomarker and well-designed, prospective, clinical 
studies are needed to answer this question. 
 
Merlin negativity may result in increased sensitivity of other tumor histologies to the FAK inhibitor 
GSK2256098.  A patient with metastatic melanoma in the very first cohort (80 mg BID) was noted to 
have a minor response (26% decrease).  This patient had progressed on two prior investigational small 
molecules and radiation therapy before receiving GSK2256098.  The archival tumor from this patient 
was merlin negative.  Additional laboratory and clinical studies, including evaluation of additional 
patient tumor specimens, are required to validate this hypothesis.   Approximately 43% of meningioma 
has inactivated NF2 [24].  A recent study of GSK2256098 has been initiated in patients with recurrent 
meningioma that has mutant NF2 (NCT02523014) 
Defactinib (VS-6063), a small molecule inhibitor of FAK and Pyk2, is in clinical development [25].  A 
Phase 2, double-blind, placebo-controlled study of defactinib as maintenance therapy for mesothelioma 
following first-line treatment (COMMAND), with patients stratified based on merlin status, was stopped 
for futility due to an insufficient level of efficacy (www.verastem.com).  Given that defactinib targets FAK 
and Pyk2 [25], while GSK2256098 is selective for FAK alone, it is unclear if this difference in target 
selectivity may result in different antitumor activity between the two compounds.  
A recent positive Phase 3 trial of bevacizumab in mesothelioma supports the potential use of a FAK 
inhibitor since FAK signals through VEGF pathway and VEGF/VEGFR act as an autocrine loop in 
mesothelioma [26] so the use of a FAK inhibitor may be rational. 
This study provides preliminary evidence that GSK2256098 is active in patients with recurrent, 
mesothelioma with potentially enhanced clinical activity in merlin negative mesothelioma. Future 
 14 
 
strategies could include preselecting patients for GSK2256098 by tumor merlin expression or using 
GSK2256098 in a treatment combination.  Preliminary results from a Phase Ib combination study of 
GSK2256098 and trametinib (MEK inhibitor) is ongoing and is being evaluated in multiple tumor types 
including mesothelioma [19].    
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Table 1.  Patient Characteristics  
Characteristic   No. of Patients 62 (%) 
 
Age (years)      
 Median (Range)   61 (21-84)       
Gender 
 Males/Females   39/23 (63/37) 
ECOG Performance Status  
 0/1     27/35 (44/56)  
Race 
 White (European ancestry  54 (87) 
 Black (African ancestry)   2   (3) 
 Southeast Asian   2   (3) 
 Arabic/North African     2   (3) 
 South Asian    1   (2) 
 Mixed Race    1   (2) 
Median No. of Prior Therapies  2 (1-8) 
(range) 
Tumor Types 
 Mesothelioma    29 (46) 
 Ovary     8 (13) 
 Pancreas    6 (10) 
 Colon/rectum    3 (5) 
 Kidney     3 (3) 
 Melanoma    2 (3) 
 Non-small cell lung   2 (3) 
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 Thyroid    2 (3) 
 
 Other1     7 (11) 
1 - Includes one each of angiosarcoma, bile duct cancer, bone cancer, bronchial cancer, 
hepatocellular carcinoma, cancer of the mouth, and cancer of the nasopharynx 
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Table 2.  Determination of the maximum tolerated dose  
 
Cohort  Dose (mg twice daily)  N  DLT  
1  80  1  None  
2  160  1  None  
3  300  3  None  
4  600  2  None  
5  1000  6*  Grade 2 proteinuria with dose interruption  
6  1500  5  Grade 3 asthenia 
Grade 2 fatigue  
7  1250  5  Grade 2 fatigue, nausea and vomiting  
 
*- Three additional patients enrolled (9 total) following dose escalation, no additional DLTs occurred. 
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Table 3.  Adverse Events ≥ 20% - All Doses Regardless of Causality  
Adverse Event All Grades 
n (%) 
Grade 3 
n (%)  
Any event 62 (100) Grade 3: 24 (39) 
Grade 4: 2 (3)  
Nausea  47 (76%)  0  
Diarrhea  40 (65%)  0  
Vomiting  36 (58%)  1 (2%)  
Decreased Appetite  29 (47%)  0  
Proteinuria  16 (26%)  0  
Fatigue  15 (24%)  1 (2%)  
Asthenia  14 (23%)  1 (2%)  
Increased Total Serum Bilirubin  14 (23%)  0  
Constipation 13 (21) 0 
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Increased Total Cholesterol  13 (21%)  1 (2%)  
 
 
Additional  Grade 3 adverse events n (%): Hypertriglyceridemia 3 (5), dyspnea 2 (3), hypercalcemia 2 (3), 
hypercholesterolemia 2 (3), hyperlipasemia 2 (3), hypokalemia 2 (3), lymphopenia 2 (3), pleuritic pain 
2(3), upper abdominal pain 1 (2), agitation 1 (2), increased amylase 1 (2), bile duct obstruction 1 (2), 
chest pain 1 (2), increased blood creatinine phosphokinase 1 (2), increased serum GGT 1 (2), headache 1 
(2), hypercalcemia 1 (2), hyperglycemia 1 (2), hypertension 1 (2), hypoacusis 1 (2), hypokalemia 1 (2), 
hypophospatemia 1 (2), interstitial lung disease 1  (2), loss of consciousness 1 (2), musculoskeletal pain 1 
(2), neutropenia 1 (2), osteoarthritis 1 (2), pericardial effusion 1 (2), pathological fracture 1 (2), 
peripheral sensory neuropathy 1 (2), pleural effusion 1 (2), pleural neuroplasm 1 (2), sciatica 1 (2), tumor 
pain 1 (2) 
Grade 4  adverse events n (%):  Increased blood creatinine phosphokinase 1 (2), cerebrovascular 
accident 1 (2) 
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Table 4:  Summary of GSK2256098 pharmacokinetic parameters after single and repeat dose 
administration of GSK2556098 on day 1 and day 15 (Parts 1-3) 
 
Dose regimen Day 1 n 
Cmax,
a 
ng/mL 
tmax,
b 
h 
AUC0-,
a 
h•ng/mL 
t1/2,
a 
h 
 80 mg  1 203 3.0 1013 4.5 
160 mg  1 392 4.0 1910 5.5 
300 mg  3 2439 (30) 1.5 (1.0, 2.0) 9962 (39) 9.0 (62) 
600 mg  2 6006 (45) 2.3 ( 1.5, 3.0) 20094 (45) 4.7 (23) 
750 mg  3 4035 (22) 3.2 (1.5, 3.5) 19258 (42) 4.7 (34) 
1000 mg  39 7058 (46) 2.1 (1.0, 6.1) 33528 (45) 4.4 (25) 
1250 mg  5 8557 (57) 3.0 (2.5, 4.0) 40136 (65) 5.1 (40) 
1500 mg  5 10452 (47) 3.0 (2.1, 4.0) 50266 (48) 4.0 (16) 
Dose regimen Day 15 n 
Cmax,
a 
ng/mL 
tmax,
b 
h 
AUC0-,
a 
h•ng/mL 
C,
a 
ng/mL 
80 mg BID
 
1 239 3.0 1110 21.2 
160 mg BID 1 482 4.0 2783 0 
300 mg BID 3 1766 (29) 2.0 (1.5, 2.0) 8603 (37) 233 (56) 
600 mg BID 2 2635 (164) 1.4 (1.3, 1.5) 9549 (134) 337 (31) 
750 mg BID 3 4130 (6.3) 3.0 (1.1, 4.0) 15062 (30) 242 (63) 
1000 mg BID 34 5946 (33) 2.1 (1.0, 8.0) 24758 (26) 465 (67) 
1250 mg BID 3 6433 (55) 3.0 (2.1, 3.0) 24803 (81) 285 (56) 
1500 mg BID 3 8806 (6.3) 2.0 (1.5, 3.0) 32223 (9.0) 316 (88) 
a
 Data reported as geometric mean (CV%)  
b
 Tmax reported as median (range). 
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Table 5.  Response Characteristics of Selected Patients 
Tumor type Merlin 
status 
Dose (mg 
twice daily) 
Best response % Decrease in 
Tumor from 
Baseline 
Duration on 
Study (days) 
Melanoma Negative 80 SD 26 377 
Mesothelioma Negative 300 SD 13 191 
Mesothelioma Positive 1000 SD1 17 294 
Mesothelioma Negative 1000 SD 15 169 
Nasopharynx ND2 1000 SD 25 209 
Kidney ND2 1000 SD 6 452 
 
1 - By independent review using modified RECIST for mesothelioma, this patient had an unconfirmed PR 
(34% decrease from baseline) 
2 - Not determined 
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Figure Legends 
Figure 1.  Inhibition of pFAK activity in tumor at 750, 1000, and 1500 mg twice daily BID in patients 
receiving GSK2256098.    
Figure 2.  Three dimensional plot of maximum reduction in tumor size (RECIST 1.1), duration on 
treatment, and tumor type.  Merlin status is provided in patients with mesothelioma and in one patient 
with melanoma (positive, negative, or unknown). 
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SUPPLEMENTAL ONLINE MATERIAL 
Administration of GSK2256098 
Patients were instructed to take GSK2256098 twice daily, orally 30 minutes after a light meal was 
completed.  While in clinic for PK sampling periods, GSK2256098 was administered with a light meal.  A 
“light” breakfast might consist of a bowl of cereal and two pieces of toast with spreads (honey, jam, 
butter, etc).  A standardized dinner may consist of a small portion of meat (chicken, beef, lamb) plus 
vegetables/salad and either rice or a small bread roll would be the standard.   Otherwise, a serving of 
pasta or a slice of lasagne with a bread roll and salad would be appropriate. Dessert can also accompany 
the main meal (a small tart, piece of cake, small cheese platter).  For a given subject, the morning and 
evening meals were to be as similar as possible to standardize conditions associated with PK sample 
collection.  When subjects are not in clinic, they were instructed to take GSK2256098 twice daily, orally 
after a light meal of their choosing as long as it complied with the exclusionary food list (subjects must 
abstain from consuming red wine, Seville oranges, grapefruit or grapefruit juice and/or kumquats, 
pummelos, exotic citrus fruit (i.e., star fruit, bitter melon), grapefruit hybrids or fruit juices from 7 days 
prior to the first dose of study medication and throughout the remainder of the time on study. 
 
Translational research  
Pharmacokinetics 
Whole blood samples (2 mL) were collected in tubes containing EDTA and then spotted on dried blood 
spot cards.  In Part 1, samples were collected prior to dosing on Day 1 and Day 15, and at 0.5, 1, 1.5, 2, 3, 
4, 6, 8, 10, 12, 18, and 24 hours after dosing.  In Part 1, a single dose of GSK2256098 was administered 
on Day 1 and from Day 2 onwards was administered twice daily (BID) on a continuous dosing schedule.  
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Samples were also collected from patients in Part 2 (Day 1 serial PK for 12 hours post-dose and single 
pre-dose samples on Days 8, 15, 22, and 43) and Part 3 (Day 15 serial PK for 12 hours post-dose, pre- 
and post-dose on day of tumor biopsy).  Human blood samples were analyzed for GSK2256098 using a 
validated analytical method based on extraction from dried blood spots on Whatman FTA paper, 
followed by ultra high-performance liquid chromatography with tandem mass spectrometric detection 
analysis (UHPLC/MS/MS). The lower limit of quantification for GSK2256098 was 10 ng/mL, using a 3 mm 
punch taken from a 15 L dried human blood spot, with a higher limit of quantification of 10,000 ng/mL. 
GSK2256098 pharmacokinetic parameters were calculated after single and repeat dosing using standard 
noncompartmental methods. Dose proportionality was assessed using a power model and declared 
based on the pre-specified criteria (90%CI) of 0.5 to 2.0 based on the slope. To estimate the 
accumulation after repeat dosing and to assess time invariance, ratios of area under the concentration-
time curve over the dosing interval ( AUC0-) on Day 15 to AUC(0-) AUC(0-12) on Day 1 and area under 
the concentration-time curve from time zero extrapolated to infinity ( AUC0-) on Day 1, respectively 
were calculated. 
Tumor biopsy collection and determination of pFAK levels 
Tumor biopsies were mandatory for patients in Part 3 and optional for those in Parts 1 and 2.  Paired 
tumor biopsies were collected prior to dosing on Day 1 and on a day between Days 8-15, one to six 
hours after dosing.   Samples were analyzed for pFAK and total FAK by a proprietary Collaborative-
Enzyme Enhanced Reactive-immunoassay (CEER) (Prometheus Laboratories, California, USA). A 
proximity based immunoassay, the CEER assay leverages a multiplexed immune-microarray platform 
combined with triple-antibody-enzyme channeling signal amplification. Specific signal amplification 
occurs when target proteins (pFAK and FAK) captured on an antibody microarray co-localize with two 
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additional detector-antibodies linked with channeling enzymes (horseradish peroxidase, HRP and 
glucose oxidase, GO).  pFAK levels were normalized to total FAK.  
Evaluation of circulating tumor, endothelial, and endothelial progenitor cells 
Blood was collected prior to dosing on Day 1, 15, 30, and 60 for the isolation of circulating tumor cells 
(CTCs).  Measurement of CTCs was performed using the CellSearch method (Veridex, Raritan, NJ, USA).  
In addition, a telomerase activity based method which can detect CTCs with a high sensitivity and 
specificity was also used [16].  Additional blood was collected prior to dosing on Day 1 and on Days 30 
and 60 and enumeration of circulating endothelial cells (CECs) and circulating endothelial progenitor 
cells (CEPs) was performed.  Measurement of CECs was performed using previously published methods 
[17, 18].  Measurement of CEPs was performed using four color flow cytometry after progenitor cell 
enrichment [17]. 
Determination of merlin status 
 Paraffin-embedded, archival tumor samples were required for all patients.  Merlin (the protein product 
of the NF2 gene) status was determined by immunohistochemistry of formalin fixed paraffin embedded 
(FFPE) archival samples collected from patients with mesothelioma (n=29) and a patient with melanoma 
(n=1). The immunohistochemistry assay was developed and conducted by Mosaic Laboratories (Lake 
Forest, California, USA). The primary antibody included an NF2 antibody (C-18): sc332, Santa Cruz 
Biotechnology (Dallas, Texas, USA). A cell line tissue microarray comprising a total of six high, moderate 
and low merlin expressors and a rabbit IgG served as the positive and negative control, respectively.  
Merlin status from archived tumor tissue was recorded as the percentage of cells that stain at +2, +3 
using the above assay and then dichotomized as either “Merlin Negative” if the percentage of neoplastic 
cells stained in the intensity staining category 3 and 2 equaled 0 or was less than 10 in category 2, or 
“Merlin Positive” otherwise.   
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